Targeting the CXCL9/CXCL10-CXCR3+ CD8+ T Cell Axis: Unraveling Anti-PD-1 Antibody-Associated Cardiotoxicity in Pressure Overload Heart Failure
Posted inCardiology news

Targeting the CXCL9/CXCL10-CXCR3+ CD8+ T Cell Axis: Unraveling Anti-PD-1 Antibody-Associated Cardiotoxicity in Pressure Overload Heart Failure

Anti-PD-1 antibody exacerbates pressure overload-induced heart failure by promoting CXCR3+ CD8+ T cell infiltration, which impairs cardiomyocyte mitochondrial function via granzyme B and perforin. This study identifies a novel immunopathogenic mechanism and therapeutic targets to mitigate cardiotoxicity.
Antibody–Drug Conjugates and Heart Risk in HER2-Positive Advanced Breast Cancer: What Clinicians Need to Know
Posted inCardiology news Oncology

Antibody–Drug Conjugates and Heart Risk in HER2-Positive Advanced Breast Cancer: What Clinicians Need to Know

A 2025 meta-analysis of 9,538 patients found trastuzumab emtansine (T‑DM1) carries the lowest incidence of LVEF decline (0.94%), while trastuzumab deruxtecan (T‑DXd) and trastuzumab-based combinations show similar, modest rates (≈4–5%). Trial selection and monitoring practices limit generalizability; baseline cardiac assessment and individualized surveillance remain essential.
Sacubitril-Valsartan for Cardiac Protection During Breast Cancer Therapy: Insights from the PRADA II Trial
Posted inCardiology news Oncology Specialties

Sacubitril-Valsartan for Cardiac Protection During Breast Cancer Therapy: Insights from the PRADA II Trial

The PRADA II trial evaluated sacubitril-valsartan for preventing cardiac dysfunction during anthracycline-based breast cancer therapy. While it did not significantly preserve left ventricular ejection fraction, improvements in myocardial strain and cardiac biomarkers suggest a potential role in cardioprotection.